Table 4.
Stratification analyses of association between polymorphisms and PFS or OS in lung cancer patients.
| PFS/OS | Polymorphism | Genotype | Subgroup | Additive | Dominant | Recessive | |||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | ||||
| PFS | rs17292622 | RPA1 | TNM2 | 1.56 (0.98-2.48) | 0.060 | 1.89 (1.06-3.38) | 0.032 | 1.34 (0.49-3.67) | 0.563 |
| OS | rs2228006 | PMS2 | ≤60 | 0.31 (0.11-0.87) | 0.027 | 0.31 (0.11-0.87) | 0.027 | ||
| rs1062372 | PMS2 | LUAD | 0.49 (0.20-1.20) | 0.121 | 0.58 (0.18-1.81) | 0.347 | 0.16 (0.03-0.95) | 0.043 | |
Additive model: comparison between minor allele subjects and major allele subjects. Dominant model: comparison between minor allele carriers and major homozygous subjects. Recessive model: comparison between major allele carriers and minor homozygous subjects. OR: odds ratio; CI: confidence interval. ∗P < 0.05.